Correlation Between Inhibrx and Kura Oncology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Kura Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Kura Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Kura Oncology, you can compare the effects of market volatilities on Inhibrx and Kura Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Kura Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Kura Oncology.

Diversification Opportunities for Inhibrx and Kura Oncology

0.61
  Correlation Coefficient

Poor diversification

The 3 months correlation between Inhibrx and Kura is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Kura Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kura Oncology and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Kura Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kura Oncology has no effect on the direction of Inhibrx i.e., Inhibrx and Kura Oncology go up and down completely randomly.

Pair Corralation between Inhibrx and Kura Oncology

Given the investment horizon of 90 days Inhibrx is expected to generate 0.48 times more return on investment than Kura Oncology. However, Inhibrx is 2.09 times less risky than Kura Oncology. It trades about -0.06 of its potential returns per unit of risk. Kura Oncology is currently generating about -0.22 per unit of risk. If you would invest  1,628  in Inhibrx on September 20, 2024 and sell it today you would lose (173.00) from holding Inhibrx or give up 10.63% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Inhibrx  vs.  Kura Oncology

 Performance 
       Timeline  
Inhibrx 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Kura Oncology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Inhibrx and Kura Oncology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inhibrx and Kura Oncology

The main advantage of trading using opposite Inhibrx and Kura Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Kura Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kura Oncology will offset losses from the drop in Kura Oncology's long position.
The idea behind Inhibrx and Kura Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance